Blue Trust Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 35.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,386 shares of the medical research company's stock after selling 1,296 shares during the period. Blue Trust Inc.'s holdings in Amgen were worth $622,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of AMGN. AMF Tjanstepension AB lifted its holdings in Amgen by 16.9% during the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company's stock valued at $38,825,000 after purchasing an additional 17,387 shares in the last quarter. Creative Planning lifted its stake in shares of Amgen by 8.6% during the 3rd quarter. Creative Planning now owns 197,457 shares of the medical research company's stock valued at $63,402,000 after buying an additional 15,564 shares in the last quarter. Swedbank AB increased its stake in Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock worth $173,639,000 after buying an additional 5,751 shares in the last quarter. Inspire Advisors LLC purchased a new position in shares of Amgen in the third quarter valued at about $204,000. Finally, Stratos Wealth Partners LTD. lifted its holdings in Amgen by 14.4% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 29,029 shares of the medical research company's stock worth $9,354,000 after purchasing an additional 3,658 shares in the last quarter. Institutional investors own 76.50% of the company's stock.
Amgen Stock Performance
Amgen stock traded up $3.66 during midday trading on Thursday, hitting $297.93. 2,318,955 shares of the company were exchanged, compared to its average volume of 3,120,625. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market capitalization of $160.05 billion, a PE ratio of 39.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.56. The business has a fifty day simple moving average of $275.15 and a two-hundred day simple moving average of $300.77. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.
Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts forecast that Amgen Inc. will post 20.6 earnings per share for the current year.
Amgen Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.20%. Amgen's dividend payout ratio (DPR) is presently 126.09%.
Wall Street Analyst Weigh In
AMGN has been the topic of several recent analyst reports. Redburn Partners reduced their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Wells Fargo & Company lowered their price target on shares of Amgen from $335.00 to $280.00 and set an "equal weight" rating for the company in a report on Friday, January 10th. Piper Sandler upped their price objective on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $314.09.
Read Our Latest Research Report on Amgen
Insider Buying and Selling at Amgen
In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock worth $10,410,596 in the last three months. 0.69% of the stock is owned by corporate insiders.
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
